The company has transferred the technology to produce Hib meningitis vaccine which is now commercialized as a pentavalent vaccine in Asia. BioNet has recently filed a patent application for its new Recombinant Acellular Pertussis Vaccine which is now evaluated in clinical trial. BioNet is uniquely positioned as a major partner in technology transfer and market access globally.